SCHEMBL27252329

SCHEMBL27252329

N#Cc1cnc(Nc2ccc(Cl)nc2)c(N)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 1/20 0.40
▸ PIK3CA P42336 1/20 0.39
▸ GRM4 Q14833 1/20 0.39
▸ JAK2 O60674 6/20 0.38
▸ JAK1 P23458 6/20 0.38
▸ KCNQ3 O43525 2/20 0.38
▸ KCNQ2 O43526 2/20 0.38
▸ KCNQ1 P51787 2/20 0.38
▸ KCNE1 P15382 1/20 0.38
▸ TRPA1 O75762 1/20 0.38
▸ SCN5A Q14524 1/20 0.38
▸ HTT P42858 1/20 0.36
▸ BACE1 P56817 3/20 0.35
▸ CTSD P07339 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27261311 0.81 TNF (0.41) TNFGRM4JAK2JAK1KCNQ3
SCHEMBL27252264 0.81 KDM4E (0.58) TNFPIK3CAJAK2JAK1KCNQ3
SCHEMBL29310772 0.78 POLB (0.46) TNFJAK2KCNQ3KCNQ2KCNQ1
SCHEMBL27252256 0.78 KDM4E (0.44) TNFPIK3CAJAK2JAK1KCNQ3
SCHEMBL7185783 0.73 EGFR (0.53) PIK3CASYK
SCHEMBL2543646 0.73 ADRA2A (0.41) KDM4EALDH1A1ABCG2
SCHEMBL2543648 0.73 ADRA2A (0.53) PIK3CAKDM4ESYK
SCHEMBL31493104 0.72 PIK3CD (0.45) HTTGRM5
SCHEMBL23927057 0.72 PIK3CA (0.57) TNFPIK3CAGRM4KCNQ3KCNQ2
SCHEMBL30079596 0.72 PIK3CA (0.57) TNFPIK3CAGRM4KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 — — US disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 — — US disclosed
WO-2024062089-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-03-28 — — WO disclosed
WO-2024062090-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 TNF 1724/4885PIK3CA 1197/4885GRM4 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback